FBRX
Forte Biosciences, Inc.·Healthcare
21.47
2.142%(−0.47)
Close PriceLast Updated: — ET
52W L: $7.7852W H: $35.80
FBRX NEWS
businesswire.com
May 11
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's Board of Directors approved the grant of equity awards in the form of options to purchase a total of 50,000 shares of its c.
businesswire.com
May 11
Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its first quarter 2026 financial results and provided a business update. “FB102 received Fast Track Designation from the FDA in celiac disease, highlighting the unmet need and reinforcing FB102's potential to address the high unmet need in celiac disease. The clinical development for FB102 continue.
seekingalpha.com
Apr 10
Forte Biosciences: Stunning Bull Run Could Continue Thanks To Near-Term Data Readouts
Forte Biosciences has rebounded from near-liquidation, raising $150m this week and advancing FB102, its multi-indication anti-CD122 antibody, on multiple fronts. FB102 demonstrated statistically significant Phase 1b efficacy in Celiac disease, positioning FBRX as a potential frontrunner for first drug approval in this indication. Upcoming Phase 1b data in vitiligo and alopecia areata, both large and competitive markets, represent major catalysts for FBRX in 2024.
businesswire.com
Apr 8
Forte Biosciences Announces Pricing of $150 Million Public Offering
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,709,936 shares of its common stock at a price to the public of $26.27 per share. In addition, Forte has granted the underwriters a 30-day option to purchase up to an additional 856,490 shares of its common stock at the public offering price, less the underwriting discounts and comm.
businesswire.com
Apr 8
Forte Biosciences Announces Proposed Public Offering
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock. All of the shares of common stock are being offered by Forte. The proposed offering is su.
defenseworld.net
Apr 2
Forte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX)
Forte Biosciences, Inc. (NASDAQ: FBRX - Get Free Report) was the target of some unusual options trading on Wednesday. Investors purchased 30,205 call options on the stock. This represents an increase of 1,663% compared to the typical daily volume of 1,713 call options. Forte Biosciences Stock Performance NASDAQ: FBRX opened at $24.86 on Thursday. The stock has
